0001209191-20-058263.txt : 20201113
0001209191-20-058263.hdr.sgml : 20201113
20201113155351
ACCESSION NUMBER: 0001209191-20-058263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201112
FILED AS OF DATE: 20201113
DATE AS OF CHANGE: 20201113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McClellan William D. Jr.
CENTRAL INDEX KEY: 0001689402
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37785
FILM NUMBER: 201311299
MAIL ADDRESS:
STREET 1: C/O APOLLO ENDOSURGERY, INC., 1120 S.
STREET 2: CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300
CITY: AUSTIN
STATE: TX
ZIP: 78746
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REATA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001358762
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113651945
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5320 LEGACY DRIVE
CITY: PLANO
STATE: TX
ZIP: 75024
BUSINESS PHONE: 972-865-2219
MAIL ADDRESS:
STREET 1: 5320 LEGACY DRIVE
CITY: PLANO
STATE: TX
ZIP: 75024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-12
0
0001358762
REATA PHARMACEUTICALS INC
RETA
0001689402
McClellan William D. Jr.
5320 LEGACY DRIVE
PLANO
TX
75024
1
0
0
0
Class A common stock
2020-11-12
4
C
0
4000
A
4000
D
Class A common stock
2020-11-12
4
S
0
2542
172.4384
D
1458
D
Class A common stock
2020-11-12
4
S
0
970
173.2148
D
488
D
Class A common stock
2020-11-12
4
S
0
488
174.8196
D
0
D
Stock Option (right to buy)
25.52
2020-11-12
4
M
0
4000
0.00
D
2027-06-14
Class B common stock
4000
2000
D
Class B common stock
2020-11-12
4
M
0
4000
25.52
A
Class A common stock
4000
4000
D
Class B common stock
2020-11-12
4
C
0
4000
D
Class A common stock
4000
0
D
The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $171.88 to $172.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $172.88 to $173.87. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $173.91 to $174.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The options vested in 4 equal installments on September 14, 2017, December 14, 2017, March 14, 2018, and June 14, 2018.
/s/ Tracy Herson, attorney-in-fact
2020-11-13